Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D3UQO1
|
|||
| Drug Name |
4D-110
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Choroideremia [ICD-11: 9B61] | Phase 1 | [1] | |
| Company |
4D Molecular Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Rab proteins geranylgeranyltransferase component A 1 (CHM) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04483440) Phase 1 Open-Label, Dose-Escalation Study of the Safety, Tolerability and Preliminary Efficacy of Intravitreal 4D-110 in Patients With Choroideremia. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of 4D Molecular Therapeutics | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.